ENTX

Quote

Short

News

Articles

Message Board

Entera Bio Ltd. (NASDAQ : ENTX ) News

News Releases

ENTX News Releases

June 22, 2026 08:30:00 am

GlobeNewswire

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

June 16, 2026 08:33:11 am

GlobeNewswire

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

June 15, 2026 08:45:00 am

GlobeNewswire

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

May 28, 2026 08:50:00 am

GlobeNewswire

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

May 11, 2026 02:44:33 am

SeekingAlpha

Entera Bio GAAP EPS of -$0.07 beats by $0.02

May 08, 2026 04:05:00 pm

GlobeNewswire

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

April 20, 2026 01:21:44 pm

SeekingAlpha

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

April 20, 2026 11:59:00 am

GlobeNewswire

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

April 14, 2026 08:45:00 am

GlobeNewswire

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

April 06, 2026 01:50:00 pm

PR Newswire

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account